Major depressive disorder: advances in neuroscience research and translational applications
Z Li, M Ruan, J Chen, Y Fang - Neuroscience bulletin, 2021 - Springer
Major depressive disorder (MDD), also referred to as depression, is one of the most common
psychiatric disorders with a high economic burden. The etiology of depression is still not …
psychiatric disorders with a high economic burden. The etiology of depression is still not …
Targeting glutamate signalling in depression: progress and prospects
Major depressive disorder (MDD) is severely disabling, and current treatments have limited
efficacy. The glutamate N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine was …
efficacy. The glutamate N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine was …
Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies
TH Pham, AM Gardier - Pharmacology & therapeutics, 2019 - Elsevier
Ketamine, a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor, displays
a fast antidepressant activity in treatment-resistant depression and in rodent models of …
a fast antidepressant activity in treatment-resistant depression and in rodent models of …
Ketamine—50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms
S Kohtala - Pharmacological Reports, 2021 - Springer
Over the past 50 years, ketamine has solidified its position in both human and veterinary
medicine as an important anesthetic with many uses. More recently, ketamine has been …
medicine as an important anesthetic with many uses. More recently, ketamine has been …
Ketamine: a tale of two enantiomers
The discovery of the rapid antidepressant effects of the dissociative anaesthetic ketamine,
an uncompetitive N-Methyl-D-Aspartate receptor antagonist, is arguably the most important …
an uncompetitive N-Methyl-D-Aspartate receptor antagonist, is arguably the most important …
Convergent mechanisms underlying rapid antidepressant action
Traditional pharmacological treatments for depression have a delayed therapeutic onset,
ranging from several weeks to months, and there is a high percentage of individuals who …
ranging from several weeks to months, and there is a high percentage of individuals who …
Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam‐controlled randomized clinical trial
Objectives To evaluate feasibility and effects of a sub‐anesthetic infusion dose of ketamine
versus midazolam on suicidal ideation in bipolar depression. Neurocognitive, blood and …
versus midazolam on suicidal ideation in bipolar depression. Neurocognitive, blood and …
Neuropathology of suicide: recent findings and future directions
Suicide is a major public health concern and a leading cause of death in most societies.
Suicidal behaviour is complex and heterogeneous, likely resulting from several causes. It …
Suicidal behaviour is complex and heterogeneous, likely resulting from several causes. It …
[HTML][HTML] Ketamine: neuroprotective or neurotoxic?
Ketamine, a non-competitive N-methyl-D-aspartate receptor (NMDAR) antagonist, has been
employed clinically as an intravenous anesthetic since the 1970s. More recently, ketamine …
employed clinically as an intravenous anesthetic since the 1970s. More recently, ketamine …
[HTML][HTML] Molecular mechanisms of rapid-acting antidepressants: new perspectives for developing antidepressants
T Chen, L Cheng, J Ma, J Yuan, C Pi, L Xiong… - Pharmacological …, 2023 - Elsevier
Major depressive disorder (MDD) is a chronic relapsing psychiatric disorder. Conventional
antidepressants usually require several weeks of continuous administration to exert …
antidepressants usually require several weeks of continuous administration to exert …